ClinicalTrials.gg
Not yet recruitingNCT07530367Updated Aug 3, 2026

Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis

A Phase 3 interventional study of Tofacitinib and Imatinib in Palmoplantar Pustulosis (PPP), sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Planned enrollment
10th of 19
135 · median 135
Started
2026
with 2 others
Phase 3
9 of 19
1 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Second Affiliated Hospital, Zhejiang University, School of Medicine

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 9 in phase 3, and was the 18th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.

Read the detailed description

This is a Phase III, randomized, double-blind, three-arm parallel-controlled trial. A total of 135 patients will be randomly assigned to one of three groups: tofacitinib monotherapy, imatinib monotherapy, or combination therapy. The primary endpoint is the proportion of patients achieving PPPASI 90 response at Week 16.

03

Conditions studied

  • Palmoplantar Pustulosis (PPP)

Browse trials for

Keywords

  • Palmoplantar Pustulosis
  • Tofacitinib
  • Imatinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years at the time of screening.

Diagnosis of palmoplantar pustulosis (PPP) for at least 12 weeks prior to the screening visit.

May have a history of or concurrent plaque psoriasis.

PPPASI score ≥ 12 at both the screening and baseline visits.

PPP-IGA score ≥ 3 at both the screening and baseline visits.

Presence of pustules on the palms and/or soles at both the screening and baseline visits, defined as pustule severity ≥ 2 in at least one region (one palm or one sole) based on the PPPASI.

Must have a confirmed diagnosis of PPP by photographic adjudication.

Male and/or female participants.

Female participants must not be pregnant, not be lactating (including feeding an infant by breast pump).

Exclusion criteria

Exclusion Criteria:

Significant improvement in PPP symptoms between the screening and baseline visits, defined as a reduction in PPPASI score of ≥ 5 units.

Presence of any of the following conditions: guttate psoriasis, erythrodermic psoriasis, generalized pustular psoriasis, acrodermatitis continua of Hallopeau, atopic dermatitis, dyshidrotic eczema, chronic hand eczema, or folliculitis.

Drug-induced psoriasis (e.g., first onset or current flare triggered by beta-blockers, calcium channel inhibitors, lithium preparations, or TNF inhibitors) or drug-induced pustular psoriasis (e.g., acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis).

Active infection or history of infection, as follows:

Any active infection within 14 days prior to the baseline visit.

Severe infection requiring hospitalization or intravenous anti-infective treatment within 8 weeks prior to the baseline visit.

History of opportunistic infections, recurrent infections, or chronic infections that, in the investigator's opinion, would make participation in this study harmful to the participant.

Positive test results for acute or chronic virus (HBV), virus (HCV), or (HIV). Exclusion is defined as:

HBV positive: 1) hepatitis B surface antigen positive, or 2) anti-hepatitis B core antibody positive.

HCV positive: 1) hepatitis C antibody positive, and 2) confirmed by a confirmatory HCV test (e.g., HCV polymerase chain reaction).

Any of the following tuberculosis (TB)-related conditions:

Known active TB disease.

History of active TB involving any organ system, unless adequately treated per WHO/CDC treatment guidelines and confirmed as fully recovered by consultation with a relevant specialist.

Latent TB infection (LTBI): Participants with LTBI may be rescreened once after receiving at least 4 weeks of appropriate LTBI treatment, provided that no treatment-related hepatotoxicity is evident prior to the first dose of medicinal product (/AST still ≤ 3×).

History of lymphoproliferative disorders (e.g., lymphoma) or current symptoms suggestive of lymphoproliferative disorders.

Current active or history of malignancy within 5 years prior to the screening visit, except for squamous cell carcinoma or basal cell carcinoma of the skin, or treated and considered cured in situ cervical cancer.

Presence of other inflammatory diseases, including but not limited to rheumatoid arthritis, hidradenitis suppurativa, inflammatory bowel disease, or systemic lupus erythematosus.

Major surgery (including joint surgery) within 8 weeks prior to the screening visit, or planned surgery during the study period.

Any systemic disease (e.g., cardiovascular, neurological, renal, hepatic, metabolic, gastrointestinal, hematological, coagulation disorders, immune system disease) that, in the investigator's opinion, is uncontrolled, unstable, or likely to progress to a degree during the study.

Any medical or psychiatric condition (including ongoing major depression or active suicidal ideation) that, in the investigator's opinion, may impair the participant's ability to participate in the study.

History of chronic alcohol or drug abuse within 6 months prior to the screening visit, as determined by the investigator based on medical history, interview, and examination findings.

Current or prior use of IL-17A, IL-17A/F, or IL-23 inhibitors.

Receipt of any (including attenuated vaccines) within 8 weeks prior to the baseline visit.

Vaccination not permitted during the study and within 17 weeks after the last dose of study treatment.

Laboratory abnormalities at the screening visit, including any of the following:

ALT, AST, or ALP ≥ 3×ULN.

> 1.5×ULN (unconjugated bilirubin > 1.5×ULN is acceptable if bilirubin is fractionated and direct bilirubin/total bilirubin ratio is \< 35%).

White blood cell count \< 3.0×10³/μL.

\< 1.5×10³/μL.

Lymphocyte count \< 500 cells/μL.

\< 8.5 g/dL.

Any other laboratory abnormality that, in the investigator's opinion, may interfere with the participant's ability to complete the study or confound the interpretation of study results.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Tofacitinib Monotherapy

    Tofacitinib 11 mg QD + Imatinib placebo QD

    Drug: Tofacitinib · Drug: Imatinib Placebo

  • Active comparator
    Arm 2: Imatinib Monotherapy

    Imatinib 200mg QD+Tofacitinib placebo QD

    Drug: Imatinib · Drug: tofacitinib Placebo

  • Experimental
    Arm 3: Combination Therapy

    Imatinib 200mg QD+Tofacitinib 11mg QD

    Drug: Tofacitinib · Drug: Imatinib

Interventions

  • 11 mg tablet; administered orally once daily (QD)

  • 200 mg tablet; administered orally once daily (QD)

  • Drugtofacitinib Placebo

    Matching placebo tablet; administered orally once daily (QD)

  • DrugImatinib Placebo

    Matching placebo tablet; administered orally once daily (QD)

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving PPPASI 90 Response at Week 16

    PPPASI 90 response is defined as at least 90% improvement from baseline in the Palmoplantar Pustulosis Area and Severity Index (PPPASI) score. Participants who discontinue study treatment or receive prohibited concomitant therapy prior to Week 16 will be considered non-responders.

    Time frame: 16 weeks

Secondary outcomes

  1. Proportion of Participants Achieving PPPASI 100 Response at Week 16

    PPPASI 100 response is defined as complete clearance (100% improvement from baseline) in the Palmoplantar Pustulosis Area and Severity Index (PPPASI) score at Week 16.

    Time frame: week 16

  2. Proportion of Participants Achieving at Least 4-Point Improvement in Palmoplantar Pain NRS Score at Week 16

    The Palmoplantar Pain Numeric Rating Scale (NRS) is an 11-point scale (0 = no pain, 10 = worst possible pain) used to assess pain intensity on the palms and soles. Response is defined as a ≥4-point improvement from baseline.

    Time frame: week 16

  3. Change from Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    The Dermatology Life Quality Index (DLQI) is a 10-item questionnaire that assesses the impact of skin disease on quality of life over the past week. Total score ranges from 0 to 30, with higher scores indicating greater impairment. A negative change indicates improvement.

    Time frame: Week 16

  4. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events are defined as any adverse event that occurs after the first dose of study treatment up to 28 days after the last dose. All TEAEs will be summarized by system organ class and preferred term.

    Time frame: Baseline through end of safety follow-up (up to Week 32)

  5. Incidence of Serious Adverse Events (SAEs)

    Serious adverse events are defined as any adverse event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

    Time frame: Baseline through end of safety follow-up (up to Week 32)

Other outcomes

  1. Proportion of Participants Achieving PPPASI 50/75/90/100 Response at Various Time Points

    Exploratory analysis of PPPASI response rates at intermediate and follow-up time points. PPPASI response is defined as the percentage improvement from baseline in Palmoplantar Pustulosis Area and Severity Index score. Safety Issue

    Time frame: Weeks 2, 4, 8, 12, and 24

  2. Change from Baseline in EQ-5D-5L Health Status Score

    The EQ-5D-5L is a standardized instrument for measuring health-related quality of life. It comprises a descriptive system (5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analog scale (0-100).

    Time frame: Weeks 4, 8, 12, 16, and 24

  3. Change from Baseline in Palmoplantar Itch NRS Score

    The Palmoplantar Itch Numeric Rating Scale (NRS) is an 11-point scale (0 = no itch, 10 = worst imaginable itch) used to assess itch intensity on the palms and soles.

    Time frame: Weeks 2, 4, 8, 12, 16, and 24

  4. Change from Baseline in Serum Biomarker Levels

    Exploratory analysis of changes in serum biomarkers associated with palmoplantar pustulosis pathogenesis, including but not limited to IL-17, IL-22, IL-36, and stem cell factor (SCF).

    Time frame: Baseline and Week 16

  5. Incidence of Adverse Events of Special Interest (AESIs)

    Adverse events of special interest include: serious infections, opportunistic infections, tuberculosis, neutropenia, hypersensitivity reactions, suicidal ideation/behavior, major adverse cardiovascular events (MACE), hepatic enzyme elevation/liver function abnormalities, malignancies, and inflammatory bowel disease. Safety Issue

    Time frame: Baseline through end of safety follow-up (up to Week 32)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 227 phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Dec 30, 2030
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530367
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Aug 3, 2026

Study contacts

Xiaoyong Man
Contact
manxy@zju.edu.cn
+86 13600516219

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tofacitinib · Imatinib

Start the discussion